Form 4: Kiniksa Officer Ross Moat Reports Equity Transactions

Kiniksa Pharmaceuticals' Chief Corporate & Commercial Officer, Ross Moat, reported multiple equity transactions including RSU vesting, share option grants, and tax-related share disposals.

Summary

• Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported several equity transactions on September 1 and 2, 2025.
• Acquired a total of 6,823 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs) on September 1, 2025 (1,741, 1,611, 2,477 shares) and September 2, 2025 (994 shares).
• Disposed of 2,819 Class A Ordinary Shares at a price of $33.49 and 481 Class A Ordinary Shares at a price of $34.28, totaling 3,300 shares, for tax withholding purposes.
• Received a new grant of 9,828 Restricted Share Units (RSUs) on September 1, 2025, which will vest over a four-year period, with 25% vesting on each yearly anniversary of the grant date.
• Received a new grant of 39,364 Share Options on September 1, 2025, with an exercise price of $33.49 and an expiration date of August 31, 2035. These options vest as to 25% on the first anniversary of the September 1, 2025 vesting commencement date, and then in 36 equal monthly installments thereafter.
• Following these transactions, beneficial ownership of Class A Ordinary Shares was 12,938 direct shares, and beneficial ownership of derivative securities included 9,828 new RSUs, 39,364 new share options, and remaining vested RSUs from prior grants.

Sentiment

Score: 6

Explanation: The filing reports routine insider equity transactions, including the vesting of existing awards and the grant of new long-term incentives, which is a standard part of executive compensation and generally neutral to slightly positive.

Positives

• The grant of 9,828 new Restricted Share Units and 39,364 new Share Options indicates continued long-term incentive and alignment of management interests with shareholder value.
• The exercise price of the new share options ($33.49) is consistent with the price of shares disposed for tax, reflecting the current market valuation at the time of the grant.

Negatives

• A total of 3,300 Class A Ordinary Shares were disposed of to cover tax obligations, which reduces the officer's direct beneficial ownership of the company's stock.

Future Outlook

The filing primarily reports past and scheduled equity transactions and does not provide a general future outlook for the company beyond the vesting schedules of the granted equity awards.

Industry Context

This Form 4 filing details routine insider equity transactions and does not provide information relevant to broader industry trends or competitor analysis within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The grant of new equity awards represents potential future dilution but also serves as a long-term incentive for management, aligning their interests with shareholder value creation.
• Employees: The transactions reflect standard executive compensation practices, which can influence overall compensation strategies within the company.

Next Steps

• Continued vesting of the 9,828 new Restricted Share Units over a four-year period, with 25% vesting annually from September 1, 2025.
• Continued vesting of the 39,364 new Share Options, with 25% vesting on the first anniversary of September 1, 2025, and the remainder in 36 equal monthly installments thereafter.

Key Dates

Recommendation

The filing details routine insider equity transactions, including the vesting of previously granted awards and the issuance of new long-term incentives. These are standard compensation practices and do not provide new fundamental information to warrant a change in investment recommendation for Kiniksa Pharmaceuticals.

Keywords

KNSA, Kiniksa Pharmaceuticals, Ross Moat, Form 4, insider transaction, equity compensation, Restricted Share Units, Share Options, beneficial ownership